Avidity Biosciences has filed a private placement worth around $400 million, seeking a cash infusion to help advance its pipeline of clinical-stage candidates that combine
Chris Anselmo, who has a rare form of muscular dystrophy, hopes to educate pharma on the patient journey and help new patients cope with a life-changing diagnosis.
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh